Impact of the resumption of proactive recommendation of HPV vaccination on HPV vaccination rates in Japan: an interrupted time series analysis based on the VENUS study Authors: Mahiro Sazawa, Chieko Ishiguro, Wataru Mimura, Megumi Maeda, Fumiko Murata, Haruhisa Fukuda Published: 2025 ABSTRACT AbstractIntroductionHuman papillomavirus (HPV) vaccination coverage in Japan is among the lowest worldwide (<1% in 2019). In April 2022, the Japanese government resumed proactive recommendations for routine HPV vaccination after an 8-year suspension and initiated a catch-up vaccination programme. This study aimed to assess the impact of this change in the vaccination policy on HPV vaccination rates in Japan.MethodsWe used data from the resident and vaccination registries of one municipality in Japan collected from January 2019 to June 2023. We estimated the cumulative vaccination rates for each female cohort born in the 2003–2011 fiscal years (FYs, 1 April–31 March). We also assessed the impact of the change in governmental policy by estimating the changes in the level and trend of first vaccination rates among girls eligible for routine vaccination using a segmented Poisson regression with an interrupted time series (ITS) design.ResultsWe identified 13 376 girls eligible for routine HPV vaccination (born between FY2003 and FY2011) during the study period. The FY2006 birth cohort had the highest cumulative vaccination rates for the first, second and third doses in June 2023 (33.6%, 30.2% and 27.0%, respectively). The ITS analysis shows that the level change was 1.53 (95% CI 1.24 to 1.91), which means that the first vaccination rate increased by 53% in April 2022. The trend change was 0.97 (95% CI 0.95 to 1.00), indicating that the trend of the first HPV vaccination remained almost unchanged before and after April 2022.ConclusionsThe resumption of the proactive recommendation of HPV vaccination by the Japanese government promoted HPV vaccinations. However, the changes in HPV vaccination rates and trends remain insufficient when compared with the WHO’s target of achieving 90% full vaccination coverage among girls by age 15 years. Additional efforts are required to encourage and promote vaccination in the Japanese population.Keywords: Public Health, Epidemiology, Female, Vaccination, Primary Prevention WHAT IS ALREADY KNOWN ON THIS TOPIC Human papillomavirus (HPV) vaccination coverage in Japan is among the lowest in the world (<1% in 2019) because the proactive recommendation for HPV vaccination was suspended until April 2022. No study has evaluated the impact of resuming proactive recommendations for HPV vaccination. Human papillomavirus (HPV) vaccination coverage in Japan is among the lowest in the world (<1% in 2019) because the proactive recommendation for HPV vaccination was suspended until April 2022. No study has evaluated the impact of resuming proactive recommendations for HPV vaccination. WHAT THIS STUDY ADDS In the cohort of girls born in fiscal year 2006, the cumulative vaccination rate was 24.8% in March 2023, when their eligibility for free routine vaccination programme ended. The level change in the first HPV vaccination rate among girls eligible for routine vaccination showed a 53% increase in April 2022. In contrast, the trend change was almost the same before and after April 2022. In the cohort of girls born in fiscal year 2006, the cumulative vaccination rate was 24.8% in March 2023, when their eligibility for free routine vaccination programme ended. The level change in the first HPV vaccination rate among girls eligible for routine vaccination showed a 53% increase in April 2022. In contrast, the trend change was almost the same before and after April 2022. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY This study indicates that the Japanese government and municipalities need to intensify efforts to promote HPV vaccination. This study indicates that the Japanese government and municipalities need to intensify efforts to promote HPV vaccination. Introduction Human papillomavirus (HPV) vaccination coverage in Japan is among the lowest worldwide. The HPV vaccination completion rate in Japan was <1% in 2019, which was one of the lowest of the WHO member states that have incorporated the HPV vaccine into their national immunisation programmes.1 More than 10 000 new cases of cervical cancer occur annually among women in Japan,2 which could potentially be prevented through HPV vaccination. In Japan, the national routine vaccination programme for HPV vaccination for girls in grades 6–10 has been in effect since April 2013. However, the recommendation for HPV vaccination was suspended by the Ministry of Health, Labour and Welfare (MHLW) in June 2013 because of repeated news reports of serious adverse events following vaccination, despite no evidence of a link (figure 1A).3 4 Approximately 8 years later, the Advisory Committee of the Health Sciences Council confirmed that there were no particular concerns regarding the safety of the vaccines, and the efficacy of HPV vaccination outweighed the risk of adverse events. Therefore, in November 2021, the MHLW decided to resume proactive recommendations for HPV vaccination starting in April 2022.5 In December 2021, the MHLW decided to establish a catch-up vaccination programme from April 2022 to March 2025, which was for girls eligible for routine vaccination when the proactive recommendations were suspended.6 In response to these decisions, every municipality resumed sending a vaccination screening form to each household with eligible candidates as a proactive recommendation to encourage HPV vaccination. History of the implementation of HPV vaccination-related actions by the MHLW and the municipality. *The date of the letter issued by local authorities was the last day of the previous month. The notification postcard or letter sent by the municipality included only a notification of a routine vaccination programme. The recommendation letter sent by the municipality included a letter for the notification of the routine or catch-up vaccination programme, a vaccine screening form, a list of medical institutions that provide HPV vaccination and a leaflet about the safety and efficacy of HPV vaccines. FY, fiscal year (April to March); HPV, human papillomavirus; MHLW, Ministry of Health, Labour and Welfare. However, the impact of resuming proactive recommendations for HPV vaccination in Japan has not yet been evaluated. Ueda et al7 and Yagi et al8 evaluated efforts to promote HPV vaccination in some municipalities in Japan; however, both surveys were conducted before the proactive recommendations for HPV vaccination were resumed, and the impact of the resumption was not analysed. Hence, this study aimed to evaluate the impact of resuming proactive recommendations for HPV vaccination in Japan by analysing HPV vaccination rates in a Japanese municipality before and after the policy change. This study comprised three analyses: evaluation of the number of vaccinations administered each month, assessment of the cumulative vaccination rates in each fiscal year (FY) and quantitative assessment of the impact of the change in government policies regarding HPV vaccination. Material and methods Data sources This study used data from the Vaccine Effectiveness, Networking and Universal Safety (VENUS) study.9 The data were collected in one municipality (Kanto region) between 1 January 2019 and 30 June 2023. The VENUS study included two databases: vaccination and residential registries. The vaccination registry contains information on vaccinations at public expense covered by the national vaccination programme (vaccine types, doses and dates). The residential registry includes data on birth year and month, sex and start and end dates of residence in the municipality. These data are linked to anonymised resident IDs, which allow individual vaccination statuses to be tracked. This study was approved by the Kyushu University Institutional Review Board for Clinical Research (no. 22 114–00). The national routine/catch-up vaccination programme for HPV in Japan The national routine vaccination programme for HPV vaccination targets girls from the sixth to 10th grades (approximately 12–16 years) under the Immunization Act in Japan.10 The MHLW set the standard target population as seventh-grade girls (13 years old).11 The catch-up programme was launched in April 2022 as a special measure available for a limited period under the Enforcement Order of the Immunization Act,12 which targets only girls born between FY1997 and FY2007. Each municipality is primarily responsible for implementing and managing their vaccination programmes. Generally, vaccinations are administered in health facilities. An individual voluntarily reserves an HPV vaccination appointment in a clinic or hospital. Parental approval is required for adolescents aged 12–15 years. Obtaining parental approval for catch-up vaccination is not necessary for adolescents aged ≥16 years or adults. Since 2014, the vaccines Cervarix and Gardasil have been used, requiring three doses. In April 2023, Silgard 9 was added to the national vaccination programme, which requires two doses for those younger than 15 years and three for those first vaccinated at 15 years or older. Although a quadrivalent vaccine has been approved for boys, Japan’s national routine vaccination programme does not cover boys’ vaccination as of November 2024. History of HPV vaccination-related actions implemented by the municipality In August 2020, the municipality began sending notification postcards about the routine HPV vaccination programme to households with girls in the ninth and 10th grades. In FY2021, notification letters were sent to households with girls in the sixth grade in April and girls in the ninth and 10th grades in July. These notifications did not recommend vaccination but rather aimed to inform residents about the routine vaccination programme. Following the MHLW’s decision to resume proactive recommendations, the municipality announced their recommendations in the city newsletter in February 2022. Since FY2022, the municipality has been sending recommendation letters for HPV vaccination, which include a notification of the routine programme, a leaflet with information on the safety and efficacy of HPV vaccines, vaccination screening forms and a list of medical institutions that provide HPV vaccination. Recommendation letters were sent to households with girls in the seventh and 10th grades in April 2022, eighth and ninth grades in August 2022, sixth grade in March 2023 and girls eligible for the catch-up vaccination programme in September 2022. A postcard announcing the addition of Silgard 9 to the routine and catch-up vaccination programmes was sent to all girls eligible for these programmes in March 2023 (figure 1B). As parental consent was required for girls younger than 15 years to receive the vaccine, letters for the routine vaccination programme were sent to them and their parents. Analysis 1: number of vaccinations administered per month We counted the number of routine and catch-up HPV vaccinations administered in medical institutions between 2019 and 2023. We counted girls eligible for routine HPV vaccination at least once in the municipality during the study period (born between FY2003 and FY2011) (online supplemental figure 1). For the statistical analysis, we calculated the number of routine and catch-up vaccinations administered each month. We also calculated the annual number of vaccinations, categorised according to dose and grade. Analysis 2: cumulative vaccination rates for each FY We estimated vaccination rates among girls eligible for the routine HPV vaccination programme between April 2019 and June 2023. We identified girls born between FY2003 and FY2011 and created a birth-year cohort for each FY (online supplemental figure 1). The cohort entry date (CED) for each cohort was the beginning of the FY for girls eligible for routine HPV vaccination or the beginning of FY2019, whichever occurred later. The exclusion criteria were as follows: (1) girls who were not residents of the municipality at the CED and (2) girls who became residents of the municipality after the date they entered the sixth grade because we could not verify their HPV vaccination history in other municipalities. The CED was defined as the start of the follow-up period. The end date of the follow-up period was 30 June 2023 or the end date of the FY when a girl was no longer a resident in the municipality, whichever was earlier. We calculated the annual cumulative vaccination rate for each dose (first, second and third) in each birth-year cohort by dividing the cumulative number of vaccinations administered to girls in the birth-year cohort by the number of girls in each cohort. The cumulative number of vaccinations was calculated on the last day of each FY from FY2019 to FY2022. After FY2022, we calculated the cumulative vaccination rates on the last day of June 2023. Analysis 3: quantitative assessment of the impact of the change in government policy regarding HPV vaccination We conducted an interrupted time series (ITS) analysis to evaluate the impact of changes in the HPV vaccination policy on HPV vaccination rates. ITS analysis is a useful quasiexperimental design used to evaluate the impact of interventions without randomisation.13 We assessed changes in the level and trends of the monthly rate of the first HPV vaccination before and after the resumption of proactive recommendations for HPV vaccination. Given that the recommendation by the Japanese government resumed after 1 April 2022, we defined the period from April 2021 to March 2022 as the preintervention period, April 2022 as the intervention month and the period from April 2022 to June 2023 as the postintervention period. The evaluation period started in April 2021 and was to reduce the effect of the letters sent by the municipality. The target population for this analysis was updated monthly (online supplemental figure 1). The CED was the first date of each month. The inclusion criteria for each cohort were girls who were eligible for routine HPV vaccination, aged 11–15 years (corresponding to girls in the sixth to 10th grades) in the FY of the CED, and who were residents of the municipality at the CED. The exclusion criteria were girls who had received one or more HPV vaccines before the CED based on the vaccination registry data and who became residents of the municipality after they entered the sixth grade based on the residential registry data. The latter exclusion criterion was adopted because we could not verify HPV vaccination history in other municipalities. The start and end dates of the follow-up period were the CED and the last day of the month, respectively. We determined the number of the first HPV vaccinations per month in the target population. Statistical analysis for Analysis 3 The rate of the first HPV vaccinations administered per month was defined as the number of girls who received their first HPV vaccination per 1000 people of the target population each month (hereafter, the first vaccination rate). We conducted a segmented Poisson regression to analyse the impact of resuming proactive recommendations on first vaccination rates. Segmented regression is frequently used in ITS studies.14 15 The regression model equation is as follows: Where T denotes the number of months after the first month of the observation; Yt represents the number of vaccinations at time T, Xt is an indicator for the preintervention term (0) or the postintervention term (1); S denotes the number of months after the intervention month; Nt represents the number of people in the target population at time T; ϵt is an error term and β0, β1,β2,β3 are coefficients. β0 is the number of vaccinations at baseline, β1 is the preintervention trend, β2 denotes the change in level in the intervention month and β3 denotes the change in trend after the intervention month compared with the trend before the intervention. We fit the regression equation to the data, estimated the coefficients (β0, β1,β2,β3) and calculated their p values. Autocorrelation and seasonality were checked using plots of the residuals, autocorrelation function (ACF) and partial autocorrelation function (PACF). Intercept estimates are presented in exponential forms. Statistical significance was set at p§amp;lt;0.05. All analyses were performed using R V.4.1.2. Results Analysis 1: number of vaccinations per month We identified 13 376 girls eligible for routine vaccination at least once during the study period. Figure 2 shows the bar plot of the number of vaccinations administered per month. Subgroup analysis of the monthly number of vaccinations by dose is shown in online supplemental figure 2. The number of vaccinations administered in March was higher than those administered in February or April 2020 and 2021. After October 2022, catch-up vaccinations accounted for nearly half of all HPV vaccinations administered within a month. However, the number of vaccinations administered each month declined temporarily between January and February 2023. Number of HPV vaccinations (all doses) administered per month in Analysis 1. HPV, human papillomavirus. The annual number of HPV vaccinations in the municipality’s national routine vaccination programme (all doses) was 156 in 2019, 450 in 2020, 1201 in 2021 and 2229 in 2022. The annual number of catch-up vaccinations administered (all doses) in FY2022 was 1862. Online supplemental figure 3 shows the annual number of vaccinations categorised according to dose and grade. Girls in the ninth and 10th grades comprised the majority, and sixth-grade girls were the least vaccinated. Analysis 2: cumulative vaccination rates per FY The number of girls in the target population for each birth-year cohort is shown in online supplemental figure 4. The target population size for each birth-year cohort was approximately 1500. The number of girls in each cohort gradually decreased as the school grade progressed due to censoring for moving out during the follow-up period. Cumulative vaccination rates according to birth-year cohort are shown in figure 3 and online supplemental table 1. The cumulative vaccination rates for birth-year cohorts increased annually. The highest full vaccination completion rate as of June 2023 among all cohorts was approximately 27% in the cohort born in FY2006, and the full vaccination completion rate at the end of the regular vaccination period (end of FY2022) was 24.8%. In cohorts with age older than the cohort born in FY2006, although the vaccination completion rate increased after implementing the catch-up vaccination programme, the full vaccination rate as of June 2023 was 8.0%–20.7%. In addition, the full vaccination rate in the seventh grade of each birth cohort, which was the age of the standard vaccination schedule, was consistently low. Cumulative vaccination rates per FY in Analysis 2. *The values for FY2023 were provisional as of 30 June 2023. The grey areas indicate the period covered by the catch-up vaccination programme implemented since FY2022; girls born in FY2006 were added to the catch-up vaccination programme in FY2023, and girls born in FY2007 will be added to FY2024. FY, fiscal year (April to March). Analysis 3: quantitative assessment of the impact of the change in government policy regarding HPV vaccination The size of the target population for each month is shown in online supplemental table 2. The sizes of the target populations for the first (April 2021) and last (June 2023) months of the period covered in Analysis 3 were 7311 and 6457, respectively. The age distribution in the target population for each month was the highest for the sixth grade (21%–23%) and the lowest for the 10th grade (15%–18%). The proportion of sixth grade girls in the target population increased gradually from April to March in each FY. The monthly rate of first vaccination and their regression curves, estimated using a segmented Poisson regression, are shown in figure 4. Several peaks of the first vaccination rate (the number of vaccinations/1000 girls) were observed during the study period: 11.3 (August 2021), 14.7 (April 2022), 25.8 (August 2022) and 29.9 (April 2023). The level of the first vaccination rate increased 1.53-fold (95% CI 1.24 to 1.91; p value §amp;lt;0.01). In addition, the trend increased 0.97-fold (95% CI 0.95 to 1.00; p value =0.09) during the intervention term. The data for the segmented Poisson regression are presented in online supplemental table 3. Autocorrelation and seasonality were not confirmed in the ACF or PACF plots (online supplemental figure 5). First HPV vaccination rates per month and their regression curves in Analysis 3. Grey bands indicate 95% CIs of the regression curves. CI, confidence interval; HPV, human papillomavirus. Discussion This study assessed the impact of the change in the vaccination policy on HPV vaccination rates in Japan. In this municipality, the reintroduction of a recommended HPV vaccination programme had positive outcomes from the three pattern analyses. The monthly and annual number of HPV vaccinations increased. The cumulative full vaccination rate in each birth cohort increased; for example, by approximately 22% between the end of FY2021 and June 2023 in the FY2006 birth cohort. Segment regression analysis showed that the level of the first HPV vaccination increased 1.53-fold after resuming proactive vaccination recommendations in April 2022. On the other hand, the highest cumulative full vaccination rate in June 2023 across all birth cohorts was only 27%, and in the segment regression analysis, the trend did not change before or after the resumption. The national routine programme targeted girls in the sixth to 10th grades, and the MHLW set the standard HPV vaccination schedule for girls in the seventh grade. The present study’s findings revealed that the number of vaccinations for sixth-grade girls in Analysis 1 was considerably lower than that for other grades. This might be because the municipality sends vaccine screening forms only to girls in the seventh grade and above, according to the MHLW’s standard schedule. Consequently, Analysis 1 revealed that most vaccinated girls were in the seventh grade or above, while Analysis 2 revealed that few girls in the seventh grade were fully vaccinated. According to a survey of all municipalities in Japan (1741 municipalities) (with a 100% response rate), fewer than half planned to send individual notifications to sixth-grade girls.16 By sending notifications and forms to sixth grade girls as a nationwide initiative, it may be possible to encourage earlier HPV vaccination uptake. We observed several peaks in the monthly number of vaccinations in Analysis 1 and the monthly rates of first vaccination in Analysis 3. The increases in March of each year could be attributed to a rush for vaccination by 10th graders, as this is the last grade eligible for the routine HPV vaccination programme. The increases observed in August 2021, April 2022, August 2022 and April 2023 coincided with the month or the following month when parents and girls received notifications or recommendation letters from the municipality. These results suggest that the letters encourage parents and girls to be vaccinated. In addition, these letters were sent during the summer and spring holidays. This might also have an additional positive impact because booking and getting to a health facility for vaccination during long holidays is easier. Previous studies in other municipalities in Japan also reported that sending notifications and leaflets with information about HPV vaccines and cervical cancer significantly improved HPV vaccination rates among girls of all eligible grades (grades 6–10).7 8 17 In contrast, we observed a decrease in the number of vaccinations administered between January and February 2023. This might be because some people were waiting for the addition of the Silgard 9 (9-valent vaccine) to the national vaccination programme in April 2023. Analysis 3 indicates that the rate of first vaccination increased by 53% in the intervention month. These results suggest that resuming the proactive recommendations by the national government contributed to a short-term increase in the first vaccination rate; however, it is possible that sending recommendation letters by the municipality had a more direct impact on this finding. Although the municipality has been sending letters since 2021, the content of the letters differed significantly before and after the proactive recommendations were resumed. The letter in 2021 announced the routine HPV vaccination programme. In contrast, the letter in 2022 included recommendations for HPV vaccination, a leaflet containing information regarding the safety and efficacy of HPV vaccines, vaccination screening forms and a list of medical facilities. At the very least, the MHLW’s decision to resume proactive recommendations motivated the municipality to implement these interventions, increasing the HPV vaccination rate. On the other hand, Analysis 3 also shows that the trend of the first vaccination rate between the periods before and after the resumption of the proactive recommendations did not change. This suggests that resumption did not have a sufficiently significant impact on long-term trends. This may be due to the municipality sending individual letters to girls eligible for the routine vaccination programme before resuming the programme. In fact, a positive slope was already observed in the period before the intervention. Yagi et al conducted a questionnaire survey among mothers of girls eligible for the routine vaccination programme in 2015 and estimated that resuming proactive recommendations would have a small effect on encouraging vaccination and that education incorporating behavioural economics concepts would be significantly effective.18 Given the low complete vaccination rates in Analysis 2, it is necessary to implement other interventions to improve vaccination rates. The WHO has stated that its HPV vaccination target is the full vaccination of 90% of girls by age 15 years.19 In the decade following 2010, only five countries had reportedly achieved this goal.1 A more recent systematic review noted that 11 countries had over 90% coverage for full dose HPV vaccinations.20 Furthermore, other countries have reported coverage rates that approach the WHO’s target. For example, HPV vaccination coverage was estimated to be 86.4% among 14-year-old girls in Canada in 202121 and 76.7% among 15-year-old girls in England in the 2023–2024 academic year.22 In contrast, our present study indicates that the full vaccination completion rate for 15-year-old girls (born in FY2008) in Japan was only 9.5% as of June 2023. Therefore, the current situation must be substantially improved to achieve this objective. Two recommendations are proposed for future routine vaccination programmes in Japan: first, vaccination should be made more accessible to eligible populations through mass vaccination programmes. Some research groups have reported that vaccination is more likely to progress when administered in a group setting than in an individual setting, which is the current approach in Japan.23 24 By increasing the opportunities for mass vaccination nationwide, we hope that more eligible individuals will be willing to be vaccinated. Second, it is essential to enhance the awareness and understanding of HPV using effective methods. Several questionnaire surveys in Japan have shown that more than half of the surveyed Japanese girls have poor knowledge of cervical cancer screening, HPV or HPV vaccines.25 26 To improve the awareness and understanding of HPV and the illness it causes, almost all municipalities in Japan (95.5%) had already sent out HPV vaccine information leaflets to eligible girls as of January 2023, but less than half planned to send individual notices to girls in the sixth grade.16 Therefore, it will be one option to send them earlier than seventh grade to encourage earlier HPV vaccination uptake, as discussed above. In addition, previous studies in other areas have suggested other measures that might be effective, including creating opportunities for education for children or adolescents in schools or to mothers via healthcare providers in health facilities, including obstetricians or gynaecologists,27 paediatricians28 or communities.18 The catch-up vaccination programmes, which started in April 2022, were scheduled to end in March 2025. In November 2024, the MHLW has decided that if girls have had at least the first dose by March 2025, they will be able to receive free catch-up vaccinations for subsequent doses until March 2026.29 This study shows that cumulative full vaccination rates for cohorts born between FY2003 and FY2006 (17–20 years old) in June 2023 were still very low (8.0%–27.0%). This finding provides important evidence for the next step in the current catch-up vaccination programme. Given that the US Centers for Disease Control and Prevention recommends catch-up HPV vaccination for all individuals over 26 years of age,30 there may be a need for further extension of the catch-up vaccination programme until the fully vaccinated coverage of the generation aged 26 years and below is sufficiently high. Strengths and limitations The strength of this study is that it is the first to accurately estimate the cumulative vaccination rate by dose using a database that allows long-term follow-up on an individual basis in Japan. Annual government statistics calculate coverage as the number of doses given to all girls eligible for the routine HPV vaccination programme divided by the number of girls in seventh grade only, leading to an overestimation of vaccination rates. Recently, one research group reported the approximate cumulative first-time vaccination rate by dividing the number of doses given to girls in each grade by the number of girls in each grade. However, the data sources for the nominator and denominator were different.31 The MHLW is planning to develop a national vaccination registry,32 which may allow the exact rate to be estimated nationally in the near future. This study had several limitations. First, because this study used data from only one municipality, careful consideration should be given when generalising the results to other municipalities in Japan. It may be more beneficial to evaluate the impact of resuming the government’s proactive recommendation policy using data collected from populations residing in a wider geographical area in Japan. Second, Analysis 3 could not evaluate the independent effect of resuming the national proactive recommendation because the contents, timing and target of letters differed between 2021 and 2022. Third, the impact of the coronavirus pandemic was not fully considered in Analysis 3. However, in our previous study which examined annual trends in childhood vaccination coverage with measles-rubella and varicella vaccines in Japan from 2015 to 2022, we did not find a decrease in coverage before or during the COVID-19 pandemic.33 This may be because the strict lockdowns observed overseas were not implemented in Japan. In addition, because Analysis 3 only studied the period during the COVID-19 pandemic and compared it with that period, the impact of the coronavirus could be considered reduced. Fourth, we could not consider HPV vaccinations received outside the national routine vaccination programme because the municipality only records information on vaccinations at public expense in the vaccination registry. If someone were vaccinated with Silgard 9 before it was added to the national vaccination programme, they paid for it themselves. However, given the high cost of the HPV vaccine and the low vaccination rate in Japan, the number of vaccinations outside the programme is thought to be very small. Fifth, the cumulative vaccination rates for the FY2003 to FY2006 birth-year cohorts may have been underestimated because data on vaccination rates before FY2018 were not available. Nevertheless, we consider that this had little effect on the present results because the vaccination rates for those born between FY2003 and FY2006 would have been <1% before FY2019.34 Conclusion This study revealed that the number of HPV vaccinations and first HPV vaccination rates in Japan increased after resuming proactive recommendations for HPV vaccination in April 2022. In contrast, the trends in the monthly rates of first vaccination remained unchanged between before and after April 2022. The cumulative vaccination rate rapidly increased in FY2022 but was much lower than 90%, which is the target set by the WHO. These findings suggest that resuming proactive recommendations to promote routine HPV vaccination is necessary; however, consistent efforts and an update to the catch-up vaccination programme are necessary to further increase vaccination rates. Supplementary material Footnotes Funding: This study was supported by Japan Agency for Medical Research and Development (grant numbers JP21nf0101635, JP24fk0108709, and JP24mk0121297). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Patient and public involvement: Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research. Ethics approval: This study was approved by the Kyushu University Institutional Review Board for Clinical Research (no. 22114-00). The requirement for individual informed consent was waived based on Japanese ethical guidelines. Data availability statement The data used in this study are not publicly available due to the sensitive nature of the information and information governance restrictions in place to protect participant confidentiality. References Associated Data Supplementary Materials Data Availability Statement The data used in this study are not publicly available due to the sensitive nature of the information and information governance restrictions in place to protect participant confidentiality.